CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019--
Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will
present at each of the following upcoming healthcare conferences:
Chardan’s Inaugural Microbiome Summit: a corporate overview
will be presented on Thursday, March 7th at 8:10 a.m. ET in
New York, NY.
Cowen and Company 39th Annual Health Care
Conference: a corporate overview will be presented on Monday,
March 11th at 11:20 a.m. ET in Boston, MA.
Oppenheimer 29th Annual Healthcare
Conference: a corporate overview will be presented on Tuesday,
March 19th at 11:30 a.m. ET in New York, NY.
A live audio webcast of each presentation will be available under the
“Investors and Media” section of Seres’ website. A replay will become
available approximately one hour after each event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the state of bacterial diversity and
function is imbalanced. Seres’ most advanced program, SER-109, has
obtained Breakthrough Therapy and Orphan Drug designations from the U.S.
Food and Drug Administration and is in Phase 3 development for recurrent C.
difficile infection. SER-287 is being evaluated in a Phase 2b study
in patients with active mild-to-moderate ulcerative colitis. Seres is
developing SER-401 in a Phase 1b study in metastatic melanoma to augment
the efficacy of anti-PD-1 immunotherapy. For more information, please
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005942/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi, Ph.D., Seres Therapeutics,
Vice President, Investor Relations and Corporate